IBD Patients in Remission Can Safely Switch to Infliximab Biosimilar

Share this post

Switching to CT-P13, an infliximab biosimilar, is safe and well tolerated in patients with IBD whose disease is in remission, researchers say.
Reuters Health Information

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply